Cooper Companies Inc (NYSE:COO) has been given a consensus recommendation of “Buy” by the thirteen analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $307.90.

A number of research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Cooper Companies from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th. Wells Fargo & Co lifted their price objective on shares of Cooper Companies from $305.00 to $325.00 and gave the company an “outperform” rating in a research note on Wednesday, March 6th. Stephens lifted their price objective on shares of Cooper Companies from $305.00 to $320.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Raymond James lifted their price objective on shares of Cooper Companies from $300.00 to $325.00 and gave the company an “outperform” rating in a research note on Wednesday, March 6th. Finally, Jefferies Financial Group lifted their price objective on shares of Cooper Companies to $330.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th.

In other Cooper Companies news, insider Robert D. Auerbach sold 2,272 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $292.22, for a total transaction of $663,923.84. Following the sale, the insider now owns 2,538 shares of the company’s stock, valued at $741,654.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gary S. Petersmeyer sold 799 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $286.88, for a total transaction of $229,217.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,811 shares of company stock worth $1,107,763. Insiders own 1.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Dupont Capital Management Corp grew its stake in shares of Cooper Companies by 4.4% during the fourth quarter. Dupont Capital Management Corp now owns 881 shares of the medical device company’s stock worth $224,000 after buying an additional 37 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Cooper Companies by 1.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 2,141 shares of the medical device company’s stock worth $545,000 after purchasing an additional 37 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Cooper Companies by 0.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,360 shares of the medical device company’s stock worth $1,364,000 after purchasing an additional 41 shares during the last quarter. Raymond James Trust N.A. grew its stake in shares of Cooper Companies by 5.4% in the fourth quarter. Raymond James Trust N.A. now owns 814 shares of the medical device company’s stock worth $207,000 after purchasing an additional 42 shares during the last quarter. Finally, Rehmann Capital Advisory Group grew its stake in shares of Cooper Companies by 24.3% in the fourth quarter. Rehmann Capital Advisory Group now owns 220 shares of the medical device company’s stock worth $56,000 after purchasing an additional 43 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

NYSE COO opened at $294.81 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.27 and a quick ratio of 0.75. Cooper Companies has a 1-year low of $216.47 and a 1-year high of $299.00. The company has a market capitalization of $14.42 billion, a PE ratio of 25.64, a price-to-earnings-growth ratio of 2.27 and a beta of 0.88.

Cooper Companies (NYSE:COO) last announced its quarterly earnings data on Tuesday, March 5th. The medical device company reported $2.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.38. Cooper Companies had a net margin of 14.22% and a return on equity of 17.56%. On average, sell-side analysts anticipate that Cooper Companies will post 12.01 earnings per share for the current year.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Story: What is a stock split?

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.